Alkem Laboratories

Alkem Laboratories Liabilities

The The Liabilities of Alkem Laboratories (ALKEM.NS) as of Nov 19, 2026 is 65.24 B INR. In the previous year, The Liabilities was 52.57 B INR — a change of 24.09% (higher).

Liabilities

65.24 BINR

YoY

24.09%

Last updated:

In 2026, Alkem Laboratories's total liabilities amounted to 65.24 B INR, a 24.09% difference from the 52.57 B INR total liabilities in the previous year.

The Alkem Laboratories Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
26.36 B INR
Jan 1, 2020
36.37 B INR
Jan 1, 2021
39.61 B INR
Jan 1, 2022
52.22 B INR
Jan 1, 2023
43.22 B INR
Jan 1, 2024
48.61 B INR
Jan 1, 2025
52.57 B INR
Jan 1, 2026
65.24 B INR
The Alkem Laboratories Liabilities history
YEARLiabilitiesYoY
65.24 BINR+24.09%
52.57 BINR+8.17%
48.61 BINR+12.47%
43.22 BINR-17.24%
52.22 BINR+31.82%
39.61 BINR+8.93%
36.37 BINR+37.95%
26.36 BINR-1.64%
26.80 BINR+35.02%
19.85 BINR+13.59%
17.48 BINR-20.96%
22.11 BINR+30.63%
16.93 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alkem Laboratories Stock analysis

What does Alkem Laboratories do? Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally. Alkem Laboratories is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Alkem Laboratories's Liabilities

Alkem Laboratories's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Alkem Laboratories's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Alkem Laboratories's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Alkem Laboratories's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Alkem Laboratories’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Alkem Laboratories stock

The Liabilities of Alkem Laboratories is 65.24 B INR in 2026.

The Liabilities of Alkem Laboratories changed from 52.57 B INR to 65.24 B INR, representing a 24.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Alkem Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Alkem Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Alkem Laboratories

All Key Metrics — Alkem Laboratories